These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32921987)

  • 21. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
    Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG
    Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
    Spanheimer PM; Cyr AR; Gillum MP; Woodfield GW; Askeland RW; Weigel RJ
    Ann Surg; 2014 Apr; 259(4):793-9. PubMed ID: 24045439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.
    Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS
    Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
    Evans AH; Pancholi S; Farmer I; Thornhill A; Evans DB; Johnston SR; Dowsett M; Martin LA
    Br J Cancer; 2010 Apr; 102(8):1235-43. PubMed ID: 20386540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
    Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
    Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
    Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
    J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatostatin inhibits the development of endometrial carcinoma in endometrial carcinoma cells and a xenograft model by targeting lipid metabolism.
    Yao L; Chen S; Li W
    Arch Biochem Biophys; 2020 May; 684():108327. PubMed ID: 32142890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants.
    Pawlik A; Słomińska-Wojewódzka M; Herman-Antosiewicz A
    Eur J Nutr; 2016 Apr; 55(3):1165-80. PubMed ID: 26014809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
    Ishii Y; Papa L; Bahadur U; Yue Z; Aguirre-Ghiso J; Shioda T; Waxman S; Germain D
    Clin Cancer Res; 2011 Apr; 17(8):2292-300. PubMed ID: 21292820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
    Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
    Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MTDH mediates estrogen-independent growth and tamoxifen resistance by down-regulating PTEN in MCF-7 breast cancer cells.
    Xu C; Kong X; Wang H; Zhang N; Kong X; Ding X; Li X; Yang Q
    Cell Physiol Biochem; 2014; 33(5):1557-67. PubMed ID: 24854844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
    Hou X; Huang F; Macedo LF; Harrington SC; Reeves KA; Greer A; Finckenstein FG; Brodie A; Gottardis MM; Carboni JM; Haluska P
    Cancer Res; 2011 Dec; 71(24):7597-607. PubMed ID: 22042792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway.
    Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW
    Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
    Lu PW; Li L; Wang F; Gu YT
    J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
    Pancholi S; Ribas R; Simigdala N; Schuster E; Nikitorowicz-Buniak J; Ressa A; Gao Q; Leal MF; Bhamra A; Thornhill A; Morisset L; Montaudon E; Sourd L; Fitzpatrick M; Altelaar M; Johnston SR; Marangoni E; Dowsett M; Martin LA
    Oncogene; 2020 Jun; 39(25):4781-4797. PubMed ID: 32307447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-Breast Cancer Effect of 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione in vivo and in vitro Through MAPK Signaling Pathway.
    Zhou X; Wu X; Qin L; Lu S; Zhang H; Wei J; Chen L; Jiang L; Wu Y; Chen C; Huang R
    Drug Des Devel Ther; 2020; 14():2667-2684. PubMed ID: 32764871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.